Key terms
About DNLI
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DNLI news
Apr 08
7:34pm ET
Denali Therapeutics price target lowered to $32 from $70 at UBS
Mar 22
4:03pm ET
Denali Therapeutics files to sell 29.29M shares of common stock for holders
Mar 05
4:06am ET
Analysts Offer Insights on Healthcare Companies: Straumann Holding AG (Six Swiss: CH:STMN), Denali Therapeutics (DNLI) and arGEN X (GB:0QW0)
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Mar 01
7:47am ET
Denali Therapeutics (DNLI) Gets a Buy from Oppenheimer
Mar 01
1:00am ET
Strong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite Dilution
Feb 28
7:45am ET
Buy Rating Affirmed for Denali Therapeutics Amid Promising Pipeline and Strategic FDA Engagement
Feb 28
7:35am ET
Buy Rating Affirmed on Denali Therapeutics Amid Promising DNL310 Progress and ETV Technology Potential
Feb 28
7:31am ET
Denali Therapeutics price target lowered to $95 from $105 at H.C. Wainwright
Feb 28
7:06am ET
Buy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash Runway
Feb 28
6:59am ET
Strong Buy Rating for Denali Therapeutics: Financial Stability and Promising Clinical Advancements
Feb 28
6:28am ET
Denali Therapeutics: Strong Buy Rating Backed by Financial Fortitude and Strategic Pipeline Advancements
Feb 27
1:00pm ET
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)
Feb 27
8:31am ET
Denali Therapeutics to sell 3.24M shares at $17.07 in private placement
Feb 27
8:12am ET
Denali Therapeutics Strengthens R&D with $500M Investment
Feb 27
8:08am ET
Denali Therapeutics expects cash runway to extend into 2028
Feb 27
8:07am ET
Denali Therapeutics reports Q4 EPS (86c), consensus (80c)
Feb 22
7:04am ET
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Feb 22
6:15am ET
Buy Rating on Denali Therapeutics: Anticipating Accelerated FDA Approval with CSF HS Biomarker Breakthrough
Feb 22
1:35am ET
Buy Rating Affirmed for Denali Therapeutics Amid Favorable Biomarker-Based Approval Prospects
Feb 20
6:36pm ET
Denali Therapeutics’ treatment of MPS IIIA granted FDA orphan designation
Feb 20
8:59am ET
Denali Therapeutics ALS study failue ‘clearing event,’ says B. Riley
Feb 20
8:55am ET
Denali continues decline after Sanofi ALS study failure
Feb 19
5:30am ET
Analysts’ Top Healthcare Picks: IQVIA Holdings (IQV), Denali Therapeutics (DNLI)
Feb 16
5:45pm ET
Maintaining Buy on Denali Therapeutics: A Resilient Pipeline Despite Setbacks Offers Favorable Risk-Reward
Feb 16
5:31pm ET
Denali Therapeutics price target lowered to $27 from $32 at Citi
Feb 16
2:25pm ET
Maintaining Buy Rating: Denali Therapeutics’ Long-Term Growth Outlook Despite HIMALAYA Study Setback
Feb 16
8:14am ET
Denali Therapeutics’ ALS Drug Fails Phase 2, Yet MS Trial Continues
Feb 09
8:01am ET
Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Illumina (ILMN)
Feb 08
6:20am ET
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), BridgeBio Pharma (BBIO) and 23andMe Holding (ME)
Feb 07
9:55pm ET
Buy Rating for Denali Therapeutics Backed by Promising DNL310 Clinical Data and Accelerated Approval Potential
No recent press releases are available for DNLI
DNLI Financials
Key terms
Ad Feedback
DNLI Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DNLI Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range